10-Q Filing

AIM IMMUNOTECH INC. CIK: 946644 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0001493152-23-016763`
Period End Date	20230331
Filing Date	20230515
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 54 Income Statement 30 Cash Flow Statement 56 Stockholders Equity 16

Balance Sheet 54 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$27.05M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$23.39M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$7.45M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$7.14M	USD	Point-in-time
Funds receivable from New Jersey net operating loss	`AccountsReceivableNetCurrent`	$1.68M	USD	Point-in-time
Funds receivable from New Jersey net operating loss	`AccountsReceivableNetCurrent`	$1.76M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$455.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$548.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$36.32M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$33.16M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$155.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$195.00K	USD	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$829.00K	USD	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$792.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsGross`	$1.90M	USD	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsGross`	$1.94M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.20M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.46M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	48.08M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	48.41M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	48.41M	shares	Point-in-time
Total assets	`Assets`	$37.46M	USD	Point-in-time
Total assets	`Assets`	$40.49M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	48.08M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$963.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$377.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$696.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$806.00K	USD	Point-in-time
Current portion of operating lease liability	`OperatingLeaseLiabilityCurrent`	$178.00K	USD	Point-in-time
Current portion of operating lease liability	`OperatingLeaseLiabilityCurrent`	$178.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.84M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.36M	USD	Point-in-time
Operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$636.00K	USD	Point-in-time
Operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$659.00K	USD	Point-in-time
Commitments and contingencies (Notes 12 and 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Notes 12 and 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Series B Convertible Preferred Stock, stated value $1,000 per share, 692 and 696 issued and outstanding, respectively	`PreferredStockValue`	$692.00K	USD	Point-in-time
Series B Convertible Preferred Stock, stated value $1,000 per share, 692 and 696 issued and outstanding, respectively	`PreferredStockValue`	$696.00K	USD	Point-in-time
Common Stock, par value $0.001 per share, authorized 350,000,000 shares, 48,407,326 and 48,084,287 issued and outstanding, respectively	`CommonStockValue`	$48.00K	USD	Point-in-time
Common Stock, par value $0.001 per share, authorized 350,000,000 shares, 48,407,326 and 48,084,287 issued and outstanding, respectively	`CommonStockValue`	$48.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$418.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$418.46M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-384.21M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-380.55M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$38.47M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$56.88M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$53.30M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$34.99M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$40.49M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$37.46M	USD	Point-in-time

Income Statement 30 line items

Line Item	Tag	Value	Unit	Period
Clinical treatment programs US	`RevenueFromContractWithCustomerExcludingAssessedTax`	$33.00K	USD	1 Quarter
Clinical treatment programs US	`RevenueFromContractWithCustomerExcludingAssessedTax`	$49.00K	USD	1 Quarter
Total Revenues	`Revenues`	$33.00K	USD	1 Quarter
Total Revenues	`Revenues`	$49.00K	USD	1 Quarter
Production costs	`ManufacturingCosts`	$77.00K	USD	1 Quarter
Production costs	`ManufacturingCosts`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.05M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.04M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.29M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.07M	USD	1 Quarter
Total Costs and Expenses	`CostsAndExpenses`	$3.19M	USD	1 Quarter
Total Costs and Expenses	`CostsAndExpenses`	$4.34M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-3.15M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-4.29M	USD	1 Quarter
Gain (Loss) on investments	`GainLossOnInvestments`	$-934.00K	USD	1 Quarter
Gain (Loss) on investments	`GainLossOnInvestments`	$203.00K	USD	1 Quarter
Interest and other income	`OtherNonoperatingIncomeExpense`	$45.00K	USD	1 Quarter
Interest and other income	`OtherNonoperatingIncomeExpense`	$199.00K	USD	1 Quarter
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	$-31.00K	USD	1 Quarter
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
(Loss) on sale of assets	`GainLossOnSaleOfPropertyPlantEquipment`	$-23.00K	USD	1 Quarter
(Loss) on sale of assets	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	1 Quarter
Gain from sale of income tax operating losses	`GainFromSaleOfIncomeTaxOperatingLoss`	$-255.00K	USD	1 Quarter
Gain from sale of income tax operating losses	`GainFromSaleOfIncomeTaxOperatingLoss`	$-190.00K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.66M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.82M	USD	1 Quarter
Basic and diluted loss per share	`EarningsPerShareBasic`	$-0.08	USD	1 Quarter
Basic and diluted loss per share	`EarningsPerShareBasic`	$-0.08	USD	1 Quarter
Weighted average shares outstanding basic and diluted	`WeightedAverageNumberOfSharesIssuedBasic`	48.40M	shares	1 Quarter
Weighted average shares outstanding basic and diluted	`WeightedAverageNumberOfSharesIssuedBasic`	47.99M	shares	1 Quarter

Cash Flow Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-3.66M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.82M	USD	1 Quarter
Depreciation of property and equipment	`Depreciation`	$10.00K	USD	1 Quarter
Depreciation of property and equipment	`Depreciation`	$11.00K	USD	1 Quarter
Redeemable warrants valuation adjustment	`RedeemableWarrantsValuationAdjustment`	-	USD	1 Quarter
Redeemable warrants valuation adjustment	`RedeemableWarrantsValuationAdjustment`	$-31.00K	USD	1 Quarter
Amortization of patent, trademark rights	`AmortizationOfIntangibleAssets`	$36.00K	USD	1 Quarter
Amortization of patent, trademark rights	`AmortizationOfIntangibleAssets`	$19.00K	USD	1 Quarter
Amortization of patent, trademark rights	`AmortizationOfIntangibleAssets`	$218.00K	USD	Annual
Changes in ROU assets	`IncreaseDecreaseinRightofUseAssets`	$5.00K	USD	1 Quarter
Changes in ROU assets	`IncreaseDecreaseinRightofUseAssets`	$37.00K	USD	1 Quarter
Loss on available for sale marketable securities	`MarketableSecuritiesGainLoss`	$-19.00K	USD	1 Quarter
Loss on available for sale marketable securities	`MarketableSecuritiesGainLoss`	-	USD	1 Quarter
Gain from sale of income tax operating losses	`LossGainFromSaleOfIncomeTaxOperatingLosses`	$190.00K	USD	1 Quarter
Gain from sale of income tax operating losses	`LossGainFromSaleOfIncomeTaxOperatingLosses`	$255.00K	USD	1 Quarter
Equity-based compensation	`ShareBasedCompensation`	$82.00K	USD	1 Quarter
Equity-based compensation	`ShareBasedCompensation`	$242.00K	USD	1 Quarter
Unrealized loss (gain) on marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$203.00K	USD	1 Quarter
Unrealized loss (gain) on marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$-915.00K	USD	1 Quarter
Prepaid expenses and other current assets and other non current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-8.00K	USD	1 Quarter
Prepaid expenses and other current assets and other non current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$180.00K	USD	1 Quarter
Lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$-23.00K	USD	1 Quarter
Lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$-5.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$586.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$180.00K	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-110.00K	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-110.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.68M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.76M	USD	1 Quarter
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$598.00K	USD	1 Quarter
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$407.00K	USD	1 Quarter
Purchase of patent and trademark rights	`ProceedsFromPaymentsToAcquireIntangibleAssets`	$-7.00K	USD	1 Quarter
Purchase of patent and trademark rights	`ProceedsFromPaymentsToAcquireIntangibleAssets`	$33.00K	USD	1 Quarter
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$712.00K	USD	1 Quarter
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$720.00K	USD	1 Quarter
Proceeds from sales of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	-	USD	1 Quarter
Proceeds from sales of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$3.70M	USD	Point-in-time
Proceeds from sales of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$29.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-346.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-78.00K	USD	1 Quarter
Proceeds from sale of stock, net of issuance costs	`ProceedsFromIssuanceOrSaleOfEquity`	-	USD	1 Quarter
Proceeds from sale of stock, net of issuance costs	`ProceedsFromIssuanceOrSaleOfEquity`	$100.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$100.00K	USD	1 Quarter
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-3.66M	USD	1 Quarter
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-3.10M	USD	1 Quarter
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$32.09M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$27.05M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$28.99M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.39M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$32.09M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$27.05M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$28.99M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.39M	USD	Point-in-time
Conversion of Series B preferred	`ConversionOfSeriesBPreferred`	-	USD	1 Quarter
Conversion of Series B preferred	`ConversionOfSeriesBPreferred`	$4.00K	USD	1 Quarter

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$38.47M	USD	Point-in-time
Balance	`StockholdersEquity`	$56.88M	USD	Point-in-time
Balance	`StockholdersEquity`	$53.30M	USD	Point-in-time
Balance	`StockholdersEquity`	$34.99M	USD	Point-in-time
Common Stock issuance, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$485.00	USD	Point-in-time
Common Stock issuance, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$100.00K	USD	1 Quarter
Common stock issuance, net of costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	969.00	shares	1 Quarter
Equity based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$242.00K	USD	1 Quarter
Equity based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$82.00K	USD	1 Quarter
Series B preferred shares converted to common	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	1 Quarter
Net comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.82M	USD	1 Quarter
Net comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.66M	USD	1 Quarter
Balance	`StockholdersEquity`	$38.47M	USD	Point-in-time
Balance	`StockholdersEquity`	$56.88M	USD	Point-in-time
Balance	`StockholdersEquity`	$53.30M	USD	Point-in-time
Balance	`StockholdersEquity`	$34.99M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.